Cabergoline therapy for Cushing disease throughout pregnancy.

Obstet Gynecol

Department of Gynecology and Obstetrics and Division of Maternal-Fetal Medicine, Department of Gynecology and Obstetrics, Johns Hopkins University School of Medicine, Baltimore, Maryland.

Published: August 2013

Background: Cushing disease during pregnancy is rare and is associated with significant maternal and fetal morbidity and mortality. Transsphenoidal pituitary surgery is the first-line therapy; however, in cases of failed surgery or in patients who are not surgical candidates, medical therapy has been used to control symptoms.

Case: A 29-year-old woman with Cushing disease and a noncurative transsphenoidal pituitary surgery was successfully treated with cabergoline, a dopamine agonist. After approximately 1 year of therapy, she became pregnant. She was maintained on high-dose cabergoline throughout her pregnancy and had an uncomplicated antenatal course. She went into spontaneous labor at 38 weeks of gestation and delivered a healthy female neonate.

Conclusion: Cabergoline can be used to manage Cushing disease successfully during pregnancy with an opportunity for a favorable outcome.

Download full-text PDF

Source
http://dx.doi.org/10.1097/AOG.0b013e31829e398aDOI Listing

Publication Analysis

Top Keywords

cushing disease
16
disease pregnancy
12
transsphenoidal pituitary
8
pituitary surgery
8
cabergoline
4
cabergoline therapy
4
cushing
4
therapy cushing
4
disease
4
pregnancy
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!